FStar Therapeutics Inc (FSTX) Stock
FSTX is no longer traded. FStar Therapeutics was delisted from the Nasdaq in March 2023.
Prices on this page are historical; the last trade was March 7, 2023 at $7.12.
FStar Therapeutics stock price history
FSTX final trading statistics
- Final close
- $7.12
- Final trading day
- Mar 7, 2023
- Market cap at delisting
- $156.51M
- Shares outstanding
- 21.98M
- Final 52-week range
- $2.07 – $7.12
- Avg. volume (final 3 mo.)
- 754,700
- All-time high (split-adj.)
- $74.88 · Nov 2017
- All-time low (split-adj.)
- $2.18 · May 2022
- Return since IPO
- -84.0%
- Beta
- -0.35
- Book value / share
- $2.59
- Price / book
- 2.75
FStar Therapeutics annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2021 | $21.17M | -$31.3M | -$2.04 |
| FY2020 | $11.26M | -$25.6M | -$6.82 |
| FY2019 | $28.32M | -$23.0M | -$5.88 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About FStar Therapeutics Inc
F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments. The company's principal product candidate is FS118 and is being evaluated in a proof-of-concept Phase 2 trial in PD-1/PD-L1 acquired resistance head and neck cancer patients. It is also developing first-in-human clinical study of FS222, a bispecific antibody that is in Phase 1 clinical trial targeting the costimulatory CD137 receptor and the inhibitory PD-L1 ligand. In addition, the company is also evaluating FS120 and SB 11285 for patients with advanced cancers, which are under Phase 1 clinical trials. F-star Therapeutics, Inc. was incorporated in 2002 and is headquartered in Cambridge, the United Kingdom. As of March 8, 2023, F-star Therapeutics, Inc. operates as a subsidiary of invoX Pharma Limited.
FStar Therapeutics stock FAQ
What happened to FStar Therapeutics stock?
FStar Therapeutics stock was delisted from the Nasdaq. Its final close was $7.12 on March 7, 2023.
Is FSTX stock still trading?
No. FSTX was delisted from the Nasdaq in March 2023 and no longer trades on a U.S. exchange.
What was the last price of FSTX stock?
FSTX closed at $7.12 on its final trading day, March 7, 2023, for a market value of about $156.51M.
What were FStar Therapeutics's revenue and earnings in its last full fiscal year?
FStar Therapeutics reported revenue of $21.17M and net income of -$31.3M in fiscal 2021, its last full year as a public company.
When did FStar Therapeutics go public?
FStar Therapeutics Inc stock began trading on May 6, 2016.